LONDON, March 09, 2023--invoX Pharma has successfully completed the acquisition of F-star Therapeutics

Parties expect the merger to be completed promptly following the successful completion of the ongoing Tender OfferCAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing next-generation immunotherapies to transform the lives of patients with cancer, today announced that the Committee on Foreign Investment in the United States (“CFIUS”

LONDON, Jan. 26, 2023 (GLOBE NEWSWIRE) -- invoX Pharma (“invoX”), a wholly owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX 1177 HK), and F-star Therapeutics, Inc. (“F-star”) (NASDAQ:FSTX), today issued the following statement regarding their pending transaction in response to a media report: The parties continue working together in active discussions with the Committee on Foreign Investment in the United States (“CFIUS”) about the terms of a mitigation agreement to add

FS222 demonstrated early antitumor activity with one complete response and six disease stabilizations in patients with advanced solid tumorsCAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Dec. 06, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star” or the “Company”), a clinical-stage biopharmaceutical company pioneering bispecifics in immunotherapy so more people with cancer can live longer and improved lives, today announced new clinical data from its potentially best-in

- FS118 is Well-Tolerated Across all Dose Levels with No Serious Adverse Events Related to FS118 Therapy - Novel mechanism showing Increased Peripheral Immune Cells and LAG-3 shedding - 54.8% Disease Control Rate in PD-L1 Acquired Resistance Patients at doses > 1mg/kg, including one partial response in Anaplastic Thyroid Cancer - Further studies ongoing in Acquired Resistance Squamous Cell Carcinoma of the Head and Neck and Checkpoint Inhibitor Naïve Non-small cell lung cancer and diffuse B cell

Previously announced agreement for F-star Therapeutics to be acquired by invoX Pharma; transaction expected to close in the second half of 2022 License Agreement with Takeda to Develop and Commercialize a Novel Next-Generation Immuno-Oncology Bispecific Antibody TherapeuticFS118 Cleared the Futility Hurdle for the Initial Stage of the Head and Neck Acquired Resistance Cancer Trial Initiation of Combination Dosing with FS120 and KEYTRUDA® in Patients with Advanced Cancers under Supply Agreement w

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., July 20, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star”), operating through its subsidiary, F-star Therapeutics Ltd., a clinical-stage biopharmaceutical company pioneering bispecifics in immunotherapy so more people with cancer can live longer and improved lives, today announced that it has entered into a license agreement with Takeda. Under the terms of the agreement, F-star will grant Takeda a worldwide, exclusive roy

If you want to know who really controls F-star Therapeutics, Inc. ( NASDAQ:FSTX ), then you'll have to look at the...

Proposed ~US$161 million all-cash acquisition to accelerate invoX’s strategy to build Sino Biopharm’s International Biopharmaceutical R&D Platform outside of China, transforming the lives of patients worldwideThe transaction demonstrates the strength of F-star’s differentiated bispecific antibody technology and provides backing from a top 40 global pharmaceutical company to accelerate growth and unlock potentialF-star’s unique next-generation tetravalent (2+2) bispecific antibody platform comple

F-star Therapeutics, Inc. ( NASDAQ:FSTX ) just released its latest quarterly results and things are looking bullish...